Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.54 |
| ▸ | PGR | P06401 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 5/20 | 0.46 |
| ▸ | CES1 | P23141 | 5/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.45 |
| ▸ | CTSG | P08311 | 1/20 | 0.45 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9049808 | 0.98 | MDM2 (0.53) | MDM2SLC6A2SLC6A3PGRADRA2A | |
| SCHEMBL434807 | 0.94 | MDM2 (0.57) | MDM2SLC6A2SLC6A3PGRADRA2A | |
| SCHEMBL9356287 | 0.89 | MDM2 (0.52) | MDM2SLC6A2SLC6A3PGRADRA2A | |
| SCHEMBL10606306 | 0.87 | MDM2 (0.50) | MDM2SLC6A2SLC6A3PGRADRA2A | |
| SCHEMBL9352547 | 0.87 | CES2 (0.50) | MDM2SLC6A2SLC6A3PGRADRA2A | |
| SCHEMBL9356264 | 0.85 | CES2 (0.51) | MDM2SLC6A2SLC6A3MAPTCES2 | |
| SCHEMBL9352928 | 0.85 | CES2 (0.51) | MDM2SLC6A2SLC6A3MAPTCES2 | |
| SCHEMBL9352414 | 0.85 | CES2 (0.51) | MDM2SLC6A2SLC6A3MAPTCES2 | |
| SCHEMBL10710461 | 0.85 | CES2 (0.51) | MDM2SLC6A2SLC6A3MAPTCES2 | |
| SCHEMBL8857493 | 0.85 | CES2 (0.51) | MDM2SLC6A2SLC6A3MAPTCES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1275 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1725586-B1 | PARTIALLY LOADED ANTIBODIES AND METHODS OF THEIR CONJUGATION | SEATTLE GENETICS INC (US) | 2015-01-14 | — | — | EP | claimed |
| US-7837980-B2 | Partially loaded antibodies and methods of their conjugation | SEATTLE GENETICS, INC. (US) | 2010-11-23 | — | — | US | claimed |
| US-6635782-B2 | Using microorganism in culture media; polylactones; biodegradable, melt processability | CANON KABUSHIKI KAISHA (JP) | 2003-10-21 | — | — | US | claimed |
| US-20020160467-A1 | Polyhydroxyalkanoate and manufacturing method thereof | CANON KABUSHIKI KAISHA (JP) | 2002-10-31 | — | — | US | claimed |
| EP-1188782-A2 | Polyhydroxyalkanoate and manufacturing method thereof | CANON KABUSHIKI KAISHA (JP) | 2002-03-20 | — | — | EP | claimed |
| US-20260144883-A1 | ANTI-TROP2/EGFR ANTIBODIES AND USES THEREOF | XADCERA BIOPHARMACEUTICAL (SUZHOU) CO., LTD. (CN) | 2026-05-28 | — | — | US | disclosed |
| EP-4743115-A2 | MULTISPECIFIC ANTIBODIES AND USES THEREOF | LTZ Therapeutics Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12630652-B2 | Bispecific antibody and use thereof | KEYMED BIOSCIENCES (CHENGDU) CO., LTD (CN) | 2026-05-19 | — | — | US | disclosed |
| EP-4739396-A1 | HUMANIZED 40H3 ANTIBODY | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-4727971-A1 | METHODS AND COMPOSITIONS RELATED TO ANTIBODIES AND ANTIBODY DRUG CONJUGATES (ADCS) THAT BIND NECTIN-4 PROTEINS | Adcentrx Therapeutics Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-3494996-B1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | AGENSYS INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12594302-B2 | Single domain antibodies and their use in cancer therapies | INSTITUT CURIE (FR) | 2026-04-07 | — | — | US | disclosed |
| US-6635782-B2 | Using microorganism in culture media; polylactones; biodegradable, melt processability | CANON KABUSHIKI KAISHA (JP) | 2003-10-21 | — | — | US | disclosed |
| WO-2003043583-A2 | TREATMENT OF IMMUNOLOGICAL DISORDERS USING ANTI-CD30 ANTIBODIES | SEATTLE GENETICS, INC. (US) | 2003-05-30 | — | — | WO | disclosed |
| US-20020160467-A1 | Polyhydroxyalkanoate and manufacturing method thereof | CANON KABUSHIKI KAISHA (JP) | 2002-10-31 | — | — | US | disclosed |
| EP-1188782-A2 | Polyhydroxyalkanoate and manufacturing method thereof | CANON KABUSHIKI KAISHA (JP) | 2002-03-20 | — | — | EP | disclosed |
| EP-0412933-B1 | Coating compositions | CIBA GEIGY AG (CH) | 1994-09-14 | — | — | EP | disclosed |
| US-5183842-A | Mixture of ketoacid and amine with film-forming binder, curing | CIBA-GEIGY CORPORATION (US) | 1993-02-02 | — | — | US | disclosed |
| US-5128396-A | Corrosion inhibiting primers on metallic substrates | CIBA-GEIGY CORPORATION (US) | 1992-07-07 | — | — | US | disclosed |
| EP-0412933-A1 | Coating compositions | CIBA-GEIGY AG (CH) | 1991-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12594302-B2 | Single domain antibodies and their use in cancer therapies | FGFR4, IGSF11, FLT4 | MDM2 3792/4885SLC6A2 885/4885SLC6A3 554/4885 |
| US-20260144883-A1 | ANTI-TROP2/EGFR ANTIBODIES AND USES THEREOF | ERBB2, EGFR, ERBB3 | MDM2 2203/4885SLC6A2 1061/4885SLC6A3 783/4885 |
| US-12630652-B2 | Bispecific antibody and use thereof | CD2, CD4, SETD1B | MDM2 3382/4885SLC6A2 2834/4885SLC6A3 3286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.